EPCAM and neoplasm: Given the great interest in therapeutic immunomodulation and targeting of tumor cells with autologous lymphocytes genetically manipulated to express an scFv-based chimeric antigen T cell receptor (21), CAR-T cells were tested with our panel of three EpCAM binders.